Cullen/Frost Bankers, Inc. Cytokinetics Inc Transaction History
Cullen/Frost Bankers, Inc.
- $7.83 Billion
- Q2 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 203 shares of CYTK stock, worth $12,309. This represents 0.0% of its overall portfolio holdings.
Number of Shares
203
Previous 142
42.96%
Holding current value
$12,309
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
370Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.07 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$890 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$727 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$475 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$386 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.71B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...